Top

Published in:

Open Access 08-09-2023 | Breast Cancer

Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer

Authors: Daiqin Xiong, Jianhua Yang, Dongfeng Li, Jie Wang

Published in: Cardiovascular Toxicology | Issue 9-10/2023

Abstract

Based on a few studies, heart failure patients with breast cancer were assessed to find potential biomarkers for doxorubicin-induced cardiotoxicity. However, key immune-related transcriptional markers linked to doxorubicin-induced cardiotoxicity in breast cancer patients have not been thoroughly investigated. We used GSE40447, GSE76314, and TCGA BRCA cohorts to perform this study. Then, we performed various bioinformatics approaches to identify the key immune-related transcriptional markers and their association with doxorubicin-induced cardiotoxicity in patients with breast cancer. We found 255 upregulated genes and 286 downregulated genes in patients with doxorubicin-induced heart failure in breast cancer. We discovered that in patients with breast cancer comorbidity doxorubicin-induced cardiotoxicity, the 58 immunological genes are elevated (such as CPA3, VSIG4, GATA2, RFX2, IL3RA, and LRP1), and the 60 genes are significantly suppressed (such as MS4A1, FCRL1, CD200, FCRLA, FCRL2, and CD79A). Furthermore, we revealed that the immune-related differentially expressed genes (DEGs) are substantially associated with the enrichment of KEGG pathways, including B-cell receptor signaling pathway, primary immunodeficiency, chemokine signaling pathway, hematopoietic cell lineage, cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, MAPK signaling pathway, focal adhesion, dilated cardiomyopathy, cell adhesion molecule, etc. Moreover, we discovered that the doxorubicin-induced immune-related genes are crucially involved in the protein–protein interaction and gene clusters. The immune-related genes, including IFIT5, XCL1, SPIB, BTLA, MS4A1, CD19, TCL1A, CD83, CD200, FCRLA, CD79A, BIRC3, and IGF2R are significantly associated with a poor survival prognosis of breast cancer patients and showed diagnostic efficacy in patients with breast cancer and heart failure. Molecular docking revealed that the survival-associated genes interact with the doxorubicin with appreciable binding affinity. Finally, we validated the expression level of immune-related genes in breast cancer patients-derived cardiomyocytes with doxorubicin-induced cardiotoxicity and found that the level of RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes are consistently dysregulated. Our findings offered a basis for understanding the mechanism and pathogenesis of the cardiotoxicity caused by doxorubicin in breast cancer patients and predicted the interaction of immune-related potential biomarkers with doxorubicin.

Available only for authorised users

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. A CA: Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708CrossRef

Cherukuri, S. P., Chikatimalla, R., Dasaradhan, T., Koneti, J., Gadde, S., & Kalluru, R. (2022). Breast cancer and the cardiovascular disease: a narrative review. Cureus, 14(8), e27917. https://doi.org/10.7759/cureus.27917CrossRefPubMedPubMedCentral

Almuwaqqat, Z., Meisel, J. L., Barac, A., & Parashar, S. (2019). Breast cancer and heart failure. Heart Failure Clinics, 15(1), 65–75. https://doi.org/10.1016/j.hfc.2018.08.007CrossRefPubMed

Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., Piña, I. L., & Volgman, A. S. (2018). Cardiovascular disease and breast cancer: Where these entities intersect. Circulation, 137(8), e30–e66. https://doi.org/10.1161/CIR.0000000000000556CrossRefPubMedPubMedCentral

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., Fernandez, T. L., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., & Suter, T. M. (2016). 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37(36), 2768–2801. https://doi.org/10.1093/eurheartj/ehw211CrossRefPubMed

Yang, H., Bhoo-Pathy, N., Brand, J. S., Hedayati, E., Grassmann, F., Zeng, E., Bergh, J., Bian, W., Ludvigsson, J. F., Hall, P., & Czene, K. (2022). Risk of heart disease following treatment for breast cancer—Results from a population-based cohort study. eLife, 11, e71562. https://doi.org/10.7554/eLife.71562CrossRefPubMedPubMedCentral

McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline chemotherapy and cardiotoxicity. Cardiovascular Drugs and Therapy, 31(1), 63–75. https://doi.org/10.1007/s10557-016-6711-0CrossRefPubMedPubMedCentral

Shah, A. N., & Gradishar, W. J. (2018). Adjuvant anthracyclines in breast cancer: What is their role? The Oncologist, 23(10), 1153–1161. https://doi.org/10.1634/theoncologist.2017-0672CrossRefPubMedPubMedCentral

Sandamali, J. A. N., Hewawasam, R. P., Fernando, M. A. C. S. S., Jayatilaka, K. A. P. W., Madurawe, R. D., Sathananthan, P. P., Ekanayake, U., & Horadugoda, J. (2020). Anthracycline-induced cardiotoxicity in breast cancer patients from Southern Sri Lanka: An echocardiographic analysis. BioMed Research International, 2020, e1847159. https://doi.org/10.1155/2020/1847159CrossRef

10.

Shakir, D. K., & Rasul, K. I. (2009). Chemotherapy induced cardiomyopathy: Pathogenesis, monitoring and management. Journal of Clinical Medicine Research, 1(1), 8–12. https://doi.org/10.4021/jocmr2009.02.1225CrossRefPubMedPubMedCentral

11.

Volkova, M., & Russell, R. (2011). Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Current Cardiology Reviews, 7(4), 214–220. https://doi.org/10.2174/157340311799960645CrossRefPubMedPubMedCentral

12.

Fradley, M. G., & Neilan, T. G. (2017). Cardiovascular outcomes in anthracycline-related cardiomyopathy. JACC Clinical Electrophysiology, 3(2), 151–153. https://doi.org/10.1016/j.jacep.2016.10.004CrossRefPubMed

13.

Christidi, E., & Brunham, L. R. (2021). Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death & Disease, 12(4), 1–15. https://doi.org/10.1038/s41419-021-03614-xCrossRef

14.

Bartlett, J. J., Trivedi, P. C., & Pulinilkunnil, T. (2017). Autophagic dysregulation in doxorubicin cardiomyopathy. Journal of Molecular and Cellular Cardiology, 104, 1–8. https://doi.org/10.1016/j.yjmcc.2017.01.007CrossRefPubMed

15.

Folgueira, M. A. A. K., Carraro, D. M., Brentani, H., Patrão, D. F. da C., Barbosa, E. M., Netto, M. M., Caldeira, J. R. F., Katayama, M. L. H., Soares, F. A., Oliveira, C. T., Reis, L. F. L., Kaiano, J. H. L., Camargo, L. P., Vêncio, R. Z. N., Snitcovsky, I. M. L., Makdissi, F. B. A., da Silva e Silva, P. J., Góes, J. C. G. S., Brentani, M. M. (2005). Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11(20), 7434–7443. https://doi.org/10.1158/1078-0432.CCR-04-0548

16.

Todorova, V. K., Makhoul, I., Dhakal, I., Wei, J., Stone, A., Carter, W., Owen, A., & Klimberg, V. S. (2017). Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients. Oncology Research, 25(8), 1223–1229. https://doi.org/10.3727/096504017X14876245096439CrossRefPubMedPubMedCentral

17.

Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 139, 111708. https://doi.org/10.1016/j.biopha.2021.111708CrossRef

18.

Ghebeh, H., Lehe, C., Barhoush, E., Al-Romaih, K., Tulbah, A., Al-Alwan, M., Hendrayani, S.-F., Manogaran, P., Alaiya, A., Al-Tweigeri, T., Aboussekhra, A., & Dermime, S. (2010). Doxorubicin downregulates cell surface B7–H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7–H1 as an anti-apoptotic molecule. Breast Cancer Research, 12(4), R48. https://doi.org/10.1186/bcr2605CrossRefPubMedPubMedCentral

19.

Syukri, A., Budu, Hatta, M., Amir, M., Rohman, M. S., Mappangara, I., Kaelan, C., Wahyuni, S., Bukhari, A., Junita, A. R., Primaguna, M. R., Dwiyanti, R., & Febrianti, A. (2022). Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1-α and VEGF pathway in progressive of cardiovascular damage. Annals of Medicine and Surgery, 76, 103501. https://doi.org/10.1016/j.amsu.2022.103501CrossRefPubMedPubMedCentral

20.

Bhagat, A., Shrestha, P., & Kleinerman, E. S. (2022). The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity. International Journal of Molecular Sciences, 23(23), 14649. https://doi.org/10.3390/ijms232314649CrossRefPubMedPubMedCentral

21.

Wang, J., Zhang, J., Xiao, M., Wang, S., Wang, J., Guo, Y., Tang, Y., & Gu, J. (2021). Molecular mechanisms of doxorubicin-induced cardiotoxicity: Novel roles of sirtuin 1-mediated signaling pathways. Cellular and Molecular Life Sciences: CMLS, 78(7), 3105–3125. https://doi.org/10.1007/s00018-020-03729-yCrossRefPubMed

22.

Hao, E., Mukhopadhyay, P., Cao, Z., Erdélyi, K., Holovac, E., Liaudet, L., Lee, W.-S., Haskó, G., Mechoulam, R., & Pacher, P. (2015). Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Molecular Medicine, 21(1), 38–45. https://doi.org/10.2119/molmed.2014.00261CrossRefPubMedPubMedCentral

23.

McCaffrey, T. A., Tziros, C., Lewis, J., Katz, R., Siegel, R., Weglicki, W., Kramer, J., Mak, I. T., Toma, I., Chen, L., Benas, E., Lowitt, A., Rao, S., Witkin, L., Lian, Y., Lai, Y., Yang, Z., & Fu, S. W. (2013). Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. International Journal of Biological Sciences, 9(4), 350–360. https://doi.org/10.7150/ijbs.6058CrossRefPubMedPubMedCentral

24.

Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., Knowles, J. W., Telli, M. L., Witteles, R. M., Blau, H. M., Bernstein, D., Altman, R. B., & Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 22(5), 547–556. https://doi.org/10.1038/nm.4087CrossRefPubMedPubMedCentral

25.

Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017). GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 45(W1), W98–W102. https://doi.org/10.1093/nar/gkx247CrossRefPubMedPubMedCentral

26.

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research, 43(7), e47. https://doi.org/10.1093/nar/gkv007CrossRefPubMedPubMedCentral

27.

Breuer, K., Foroushani, A. K., Laird, M. R., Chen, C., Sribnaia, A., Lo, R., & Lynn, D. J. (2013). InnateDB: systems biology of innate immunity and beyond—Recent updates and continuing curation. Nucleic Acids Research, 41, D1228–D1233. https://doi.org/10.1093/nar/gks1147CrossRefPubMed

28.

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., & Mesirov, J. P. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America, 102(43), 15545–15550. https://doi.org/10.1073/pnas.0506580102CrossRefPubMedPubMedCentral

29.

Luo, W., & Brouwer, C. (2013). Pathview: An R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics, 29(14), 1830–1831. https://doi.org/10.1093/bioinformatics/btt285CrossRefPubMedPubMedCentral

30.

Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., & von Mering, C. (2019). STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, 47, D607–D613. https://doi.org/10.1093/nar/gky1131CrossRefPubMed

31.

Bader, G. D., & Hogue, C. W. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4(1), 2. https://doi.org/10.1186/1471-2105-4-2CrossRefPubMedPubMedCentral

32.

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research, 13(11), 2498–2504. https://doi.org/10.1101/gr.1239303CrossRefPubMedPubMedCentral

33.

Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011). pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12(1), 77. https://doi.org/10.1186/1471-2105-12-77CrossRefPubMedPubMedCentral

34.

Wang, J., Uddin, Md. N., Wang, R., Gong, Y., & Wu, Y. (2022). Comprehensive analysis and validation of novel immune and vascular remodeling related genes signature associated with drug interactions in pulmonary arterial hypertension. Frontiers in Genetics. https://doi.org/10.3389/fgene.2022.922213CrossRefPubMedPubMedCentral

35.

Yu, L.-R., Cao, Z., Makhoul, I., Daniels, J. R., Klimberg, S., Wei, J. Y., Bai, J. P. F., Li, J., Lathrop, J. T., Beger, R. D., & Todorova, V. K. (2018). Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Experimental Biology and Medicine, 243(3), 248–255. https://doi.org/10.1177/1535370217746383CrossRefPubMed

36.

Kim, Y. A., Cho, H., Lee, N., Jung, S.-Y., Sim, S. H., Park, I. H., Lee, S., Lee, E. S., & Kim, H. J. (2018). Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database. Cancer Medicine, 7(12), 6084–6092. https://doi.org/10.1002/cam4.1886CrossRefPubMedPubMedCentral

37.

Uddin, M. N., & Wang, X. (2022). Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer. Breast Cancer (Tokyo, Japan), 29(3), 541–561. https://doi.org/10.1007/s12282-022-01332-6CrossRefPubMed

38.

Uddin, Md. N., Li, M., & Wang, X. (2019). Identification of transcriptional markers and microRNA–mRNA regulatory networks in colon cancer by integrative analysis of mRNA and microRNA expression profiles in colon tumor stroma. Cells, 8(9), 1054. https://doi.org/10.3390/cells8091054CrossRefPubMedPubMedCentral

39.

Chen, J.-C., Xie, T.-A., Lin, Z.-Z., Li, Y.-Q., Xie, Y.-F., Li, Z.-W., & Guo, X.-G. (2022). Identification of key pathways and genes in SARS-CoV-2 infecting human intestines by bioinformatics analysis. Biochemical Genetics, 60(3), 1076–1094. https://doi.org/10.1007/s10528-021-10144-wCrossRefPubMed

40.

Wang, R., Chen, X., Huang, C., Yang, X., He, H., OuYang, C., Li, H., Guo, J., Yang, C., & Lin, Z. (2022). Identification of key genes with prognostic value in gastric cancer by bioinformatics analysis. Frontiers in Genetics. https://doi.org/10.3389/fgene.2022.958213CrossRefPubMedPubMedCentral

41.

Li, X., Warren, S., Pelekanou, V., Wali, V., Cesano, A., Liu, M., Danaher, P., Elliott, N., Nahleh, Z. A., Hayes, D. F., Hortobagyi, G. N., Barlow, W. E., Hatzis, C., & Pusztai, L. (2019). Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. Journal for Immunotherapy of Cancer, 7, 88. https://doi.org/10.1186/s40425-019-0563-7CrossRefPubMedPubMedCentral

42.

Chen, N., Feng, Q., Deng, J., Xiong, Y., Deng, Y.-J., Wang, M.-M., Zhou, L., Yu, Q.-W., Hu, J.-P., & Deng, H. (2020). Hdc-expressing myeloid-derived suppressor cells promote basal-like transition and metastasis of breast cancer. International Journal of Clinical and Experimental Pathology, 13(6), 1431–1443.PubMedPubMedCentral

43.

Casciello, F., Al-Ejeh, F., Kelly, G., Brennan, D. J., Ngiow, S. F., Young, A., Stoll, T., Windloch, K., Hill, M. M., Smyth, M. J., Gannon, F., & Lee, J. S. (2017). G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 114(27), 7077–7082. https://doi.org/10.1073/pnas.1618706114CrossRefPubMedPubMedCentral

44.

Connelly, J. J., Wang, T., Cox, J. E., Haynes, C., Wang, L., Shah, S. H., Crosslin, D. R., Hale, A. B., Nelson, S., Crossman, D. C., Granger, C. B., Haines, J. L., Jones, C. J. H., Vance, J. M., Goldschmidt-Clermont, P. J., Kraus, W. E., Hauser, E. R., & Gregory, S. G. (2006). GATA2 is associated with familial early-onset coronary artery disease. PLoS Genetics, 2(8), e139. https://doi.org/10.1371/journal.pgen.0020139CrossRefPubMedPubMedCentral

45.

Zhao, L., & Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Scientific Reports, 7, 44735. https://doi.org/10.1038/srep44735CrossRefPubMedPubMedCentral

46.

da Cunha Menezes Souza, L., Fernandes, F. H., Presti, P. T., Anjos Ferreira, A. L., & Fávero Salvadori, D. M. (2021). Effect of doxorubicin on cardiac lipid metabolism-related transcriptome and the protective activity of Alda-1. European Journal of Pharmacology, 898, 173955. https://doi.org/10.1016/j.ejphar.2021.173955CrossRefPubMed

47.

Standish, L. J., Sweet, E. S., Novack, J., Wenner, C. A., Bridge, C., Nelson, A., Martzen, M., & Torkelson, C. (2008). Breast cancer and the immune system. Journal of the Society for Integrative Oncology, 6(4), 158–168.PubMedPubMedCentral

48.

Zhang, Y., Bauersachs, J., & Langer, H. F. (2017). Immune mechanisms in heart failure. European Journal of Heart Failure, 19(11), 1379–1389. https://doi.org/10.1002/ejhf.942CrossRefPubMed

49.

Zhang, L., Qin, Q., Xu, C., Zhang, N., & Zhao, T. (2022). Identification of immune cell function in breast cancer by integrating multiple single-cell data. Frontiers in Immunology, 13, 1058239. https://doi.org/10.3389/fimmu.2022.1058239CrossRefPubMedPubMedCentral

50.

Ma, Z., Wang, X., Lv, Q., Gong, Y., Xia, M., Zhuang, L., Lu, X., Yang, Y., Zhang, W., Fu, G., Ye, Y., & Lai, D. (2021). Identification of underlying hub genes associated with hypertrophic cardiomyopathy by integrated bioinformatics analysis. Pharmacogenomics and Personalized Medicine, 14, 823–837. https://doi.org/10.2147/PGPM.S314880CrossRefPubMedPubMedCentral

51.

Shadrina, A. S., Shashkova, T. I., Torgasheva, A. A., Sharapov, S. Z., Klarić, L., Pakhomov, E. D., Alexeev, D. G., Wilson, J. F., Tsepilov, Y. A., Joshi, P. K., & Aulchenko, Y. S. (2020). Prioritization of causal genes for coronary artery disease based on cumulative evidence from experimental and in silico studies. Scientific Reports, 10(1), 10486. https://doi.org/10.1038/s41598-020-67001-wCrossRefPubMedPubMedCentral

52.

Zhao, X., Li, L., Yuan, S., Zhang, Q., Jiang, X., & Luo, T. (2021). SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cells. Cellular Signalling, 88, 110148. https://doi.org/10.1016/j.cellsig.2021.110148CrossRefPubMed

53.

Ning, Z., Liu, K., & Xiong, H. (2021). Roles of BTLA in Immunity and Immune Disorders. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.654960CrossRefPubMedPubMedCentral

54.

Zhao, E., Xie, H., & Zhang, Y. (2020). Predicting diagnostic gene biomarkers associated with immune infiltration in patients with acute myocardial infarction. Frontiers in Cardiovascular Medicine, 7, 586871. https://doi.org/10.3389/fcvm.2020.586871CrossRefPubMedPubMedCentral

55.

Akhter, Md. Z., & Rajeswari, M. R. (2014). Interaction of doxorubicin with a regulatory element of hmga1 and its in vitro anti-cancer activity associated with decreased HMGA1 expression. Journal of Photochemistry and Photobiology B: Biology, 141, 36–46. https://doi.org/10.1016/j.jphotobiol.2014.08.026CrossRefPubMed

56.

Mitry, M. A., & Edwards, J. G. (2015). Doxorubicin induced heart failure: Phenotype and molecular mechanisms. International Journal of Cardiology: Heart & Vasculature, 10, 17–24. https://doi.org/10.1016/j.ijcha.2015.11.004CrossRef

57.

Tuinstra, R. L., Peterson, F. C., Elgin, E. S., Pelzek, A. J., & Volkman, B. F. (2007). An engineered second disulfide bond restricts lymphotactin/XCL1 to a chemokine-like conformation with XCR1 agonist activity. Biochemistry, 46(10), 2564–2573. https://doi.org/10.1021/bi602365dCrossRefPubMed

58.

Teplyakov, A., Obmolova, G., Luo, J., & Gilliland, G. L. (2018). Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold. Proteins, 86(5), 495–500. https://doi.org/10.1002/prot.25485CrossRefPubMed

59.

Heilingloh, C. S., Klingl, S., Egerer-Sieber, C., Schmid, B., Weiler, S., Mühl-Zürbes, P., Hofmann, J., Stump, J. D., Sticht, H., Kummer, M., Steinkasserer, A., & Muller, Y. A. (2017). Crystal structure of the extracellular domain of the human dendritic cell surface marker CD83. Journal of Molecular Biology, 429(8), 1227–1243. https://doi.org/10.1016/j.jmb.2017.03.009CrossRefPubMed

60.

Herman, M., Moche, M., Flodin, S., Welin, M., Trésaugues, L., Johansson, I., Nilsson, M., Nordlund, P., & Nyman, T. (2009). Structures of BIR domains from human NAIP and cIAP2. Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 65(Pt 11), 1091–1096. https://doi.org/10.1107/S1744309109038597CrossRefPubMedPubMedCentral

61.

Hoh, F., Yang, Y. S., Guignard, L., Padilla, A., Stern, M. H., Lhoste, J. M., & van Tilbeurgh, H. (1998). Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. Structure, 6(2), 147–155. https://doi.org/10.1016/s0969-2126(98)00017-3CrossRefPubMed

62.

Katibah, G. E., Lee, H. J., Huizar, J. P., Vogan, J. M., Alber, T., & Collins, K. (2013). tRNA binding, TPR eddy fold, and subcellular localization of the human interferon-induced protein, IFIT5. Molecular cell, 49(4), 743–750. https://doi.org/10.1016/j.molcel.2012.12.015CrossRefPubMedPubMedCentral

63.

Compaan, D. M., Gonzalez, L. C., Tom, I., Loyet, K. M., Eaton, D., & Hymowitz, S. G. (2005). Attenuating lymphocyte activity: The crystal structure of the BTLA-HVEM complex. The Journal of Biological Chemistry, 280(47), 39553–39561. https://doi.org/10.1074/jbc.M507629200CrossRefPubMed

64.

Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., & Reyes, N. (2020). Binding mechanisms of therapeutic antibodies to human CD20. Science, 369(6505), 793–799. https://doi.org/10.1126/science.abb8008CrossRefPubMed

65.

Ma, X., Zhu, Y., Dong, D., Chen, Y., Wang, S., Yang, D., Ma, Z., Zhang, A., Zhang, F., Guo, C., & Huang, Z. (2022). Cryo-EM structures of two human B cell receptor isotypes. Science, 377(6608), 880–885. https://doi.org/10.1126/science.abo3828CrossRefPubMed

66.

Brown, J., Delaine, C., Zaccheo, O. J., Siebold, C., Gilbert, R. J., van Boxel, G., Denley, A., Wallace, J. C., Hassan, A. B., Forbes, B. E., & Jones, E. Y. (2008). Structure and functional analysis of the IGF-II/IGF2R interaction. The EMBO Journal, 27(1), 265–276. https://doi.org/10.1038/sj.emboj.7601938CrossRefPubMed

Title: Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer
Authors: Daiqin Xiong
Jianhua Yang
Dongfeng Li
Jie Wang
Publication date: 08-09-2023
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Heart Failure
Published in: Cardiovascular Toxicology / Issue 9-10/2023
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09806-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9-10/2023

Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases

Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways

COMP Improves Ang-II-Induced Atrial Fibrillation via TGF-β Signaling Pathway

Klotho/FGF23 Axis Regulates Cardiomyocyte Apoptosis and Cytokine Release through ERK/MAPK Pathway